Targeting IGF-1R: throwing out the baby with the bathwater?
Author Information
Author(s): Basu B, Olmos D, de Bono J S
Primary Institution: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
Conclusion
Pre-treatment free IGF-1 concentration is a predictive biomarker of clinical benefit from figitumumab at 20 mg/kg but not at 10 mg/kg in NSCLC.
Supporting Evidence
- Low IGF-1 levels are associated with prolonged survival in NSCLC.
- Pre-treatment fIGF-1 was not predictive of PFS in patients receiving chemotherapy alone.
- Figitumumab has shown anti-tumour activity in metastatic Ewing's sarcoma.
Takeaway
This study looks at a blood marker that might help doctors know which lung cancer patients will benefit from a specific treatment. It found that one level of this marker is helpful, but another level is not.
Limitations
The analysis is complicated by the small sample size and biological heterogeneity of patients, and the use of one-sided tests limits statistical power.
Participant Demographics
The study mentions that higher baseline fIGF-1 is present in females and patients with adenocarcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website